This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Prognosis of AML

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Acute myeloid leukaemia mortality is strongly related to age, with the highest mortality rates being in older people.

  • in the UK in 2014-2016, on average each year more than half (52%) of deaths were in people aged 75 and over - largely reflects higher incidence and lower survival for acute myeloid leukaemia in older people
  • age-specific mortality rates rise steadily from around age 50-54 and more steeply from around age 60-64
  • highest rates are in the 85 to 89 age group for males and females. Mortality rates are significantly higher in males than females in a number of (mainly older) age groups. The gap is widest at age 90+, when the age-specific mortality rate is 2 times higher in males than females

 

Younger adults:

  • 70-80% of adults with AML under 50 years achieve complete remission
  • postremission chemotherapy is curative in 20-30% of cases
  • allogeneic bone marrow transplantation is curative in 45-55% of cases - but bone marrow transplants are restricted to persons under 55 years of age, and often, only to those who have an HLA-matched sibling donors

Older adults:

  • 50% achieve complete remission

Reference:


Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.